Cash and cash equivalents stood at around $427 million by the end of the third quarter. The company discusses the overlap of sites for SO1 and Solar studies, aiming for a differentiated product label for their drug, and providing updates on Solar's enrollment progress for a seamless transition with a steady recruitment pace.